CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Zentalis Pharmaceuticals - ZNTL CFD

13.81
3.23%
Market Trading Hours* (UTC) Opens on Tuesday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.12
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Zentalis Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 14.25
Open* 13.89
1-Year Change* -25.72%
Day's Range* 13.69 - 14.15
52 wk Range 9.56-31.46
Average Volume (10 days) 713.66K
Average Volume (3 months) 22.85M
Market Cap 917.12M
P/E Ratio -100.00K
Shares Outstanding 70.77M
Revenue N/A
EPS -4.65
Dividend (Yield %) N/A
Beta 1.67
Next Earnings Date Feb 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 18, 2024 13.79 0.16 1.17% 13.63 14.17 13.58
Mar 15, 2024 14.25 0.47 3.41% 13.78 14.64 13.60
Mar 14, 2024 13.99 -0.95 -6.36% 14.94 15.25 13.70
Mar 13, 2024 15.17 0.74 5.13% 14.43 15.31 14.36
Mar 12, 2024 14.73 0.99 7.21% 13.74 14.96 13.31
Mar 11, 2024 13.75 -1.34 -8.88% 15.09 15.69 13.31
Mar 8, 2024 15.34 0.55 3.72% 14.79 15.69 14.76
Mar 7, 2024 14.79 0.27 1.86% 14.52 15.06 14.22
Mar 6, 2024 14.50 0.53 3.79% 13.97 14.54 13.92
Mar 5, 2024 14.17 0.01 0.07% 14.16 14.52 13.96
Mar 4, 2024 14.47 -0.57 -3.79% 15.04 15.10 14.18
Mar 1, 2024 15.20 0.40 2.70% 14.80 16.10 14.40
Feb 29, 2024 14.85 -0.67 -4.32% 15.52 16.06 14.69
Feb 28, 2024 15.37 0.78 5.35% 14.59 17.92 14.54
Feb 27, 2024 14.64 0.46 3.24% 14.18 14.92 13.89
Feb 26, 2024 14.00 0.79 5.98% 13.21 14.18 13.21
Feb 23, 2024 13.58 -0.29 -2.09% 13.87 14.53 13.42
Feb 22, 2024 13.89 0.53 3.97% 13.36 13.99 13.27
Feb 21, 2024 13.60 0.33 2.49% 13.27 14.04 13.27
Feb 20, 2024 13.68 0.99 7.80% 12.69 14.49 12.53

Zentalis Pharmaceuticals Events

Time (UTC) Country Event
Wednesday, May 8, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Zentalis Pharmaceuticals Inc Earnings Release
Q1 2024 Zentalis Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Friday, June 14, 2024

Time (UTC)

13:30

Country

US

Event

Zentalis Pharmaceuticals Inc Annual Shareholders Meeting
Zentalis Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0.014
Revenue 0 0.014
Total Operating Expense 227.287 164.96 118.787 46.845 23.797
Selling/General/Admin. Expenses, Total 54.553 40.941 33.886 8.459 4.876
Research & Development 172.734 166.801 84.901 38.386 18.921
Operating Income -227.287 -164.96 -118.787 -46.845 -23.783
Interest Income (Expense), Net Non-Operating 5.987 0.401 0.683 0.498 0.355
Other, Net -0.016 0
Net Income Before Taxes -221.3 -164.559 -118.104 -46.363 -23.428
Net Income After Taxes -220.831 -164.262 -118.548 -46.378 -23.432
Minority Interest 0.307 7.368 0.707 0.715 2.365
Net Income Before Extra. Items -236.806 -158.725 -117.841 -45.663 -21.067
Net Income -236.806 -158.725 -117.841 -45.663 -21.067
Income Available to Common Excl. Extra. Items -236.806 -158.725 -117.841 -45.663 -21.067
Income Available to Common Incl. Extra. Items -236.806 -158.725 -117.841 -45.663 -21.067
Diluted Net Income -236.806 -158.725 -117.841 -45.663 -21.067
Diluted Weighted Average Shares 52.857 42.688 28.113 34.5015 34.5015
Diluted EPS Excluding Extraordinary Items -4.48013 -3.71826 -4.19169 -1.32351 -0.61061
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -4.48013 -4.29754 -4.19169 -1.32351 -0.61061
Unusual Expense (Income) 0 -42.782
Equity In Affiliates -16.282 -1.831
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 103.916 64.953 51.754 54.193 63.461
Selling/General/Admin. Expenses, Total 15.664 11.369 11.138 12.012 19.636
Research & Development 88.252 48.584 40.616 42.181 43.825
Operating Income -103.916 -64.953 -51.754 -54.193 -63.461
Interest Income (Expense), Net Non-Operating 4.451 4.109 3.232 1.905 0.424
Other, Net
Net Income Before Taxes -99.465 -60.844 -48.522 -52.288 -63.037
Net Income After Taxes -98.86 -60.952 -48.162 -52.129 -63.054
Minority Interest 0.037 0.043 0.013 0.099 0.035
Net Income Before Extra. Items -112.527 -63.219 -54.971 -54.401 -68.357
Net Income -112.527 -63.219 -54.971 -54.401 -68.357
Income Available to Common Excl. Extra. Items -112.527 -63.219 -54.971 -54.401 -68.357
Income Available to Common Incl. Extra. Items -112.527 -63.219 -54.971 -54.401 -68.357
Diluted Net Income -112.527 -63.219 -54.971 -54.401 -68.357
Diluted Weighted Average Shares 60.79 59.277 58.134 56.807 51.117
Diluted EPS Excluding Extraordinary Items -1.85108 -1.0665 -0.94559 -0.95765 -1.33727
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.85108 -1.01167 -0.94559 -0.95765 -1.33727
Unusual Expense (Income) 0 5 0 0
Equity In Affiliates -13.704 -2.31 -6.822 -2.371 -5.338
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 451.933 350.77 345.104 68.891 26.677
Cash and Short Term Investments 437.371 339.887 338.505 67.246 25.154
Cash & Equivalents 43.069 59.714 54.951 67.246 25.154
Total Receivables, Net 6.382 0.004 0.417 0.14 0.917
Accounts Receivable - Trade, Net 0.004 0.417 0.14 0.917
Prepaid Expenses 7.521 10.636 6.182 1.505 0.606
Total Assets 539.31 454.507 365.555 87.481 40.998
Property/Plant/Equipment, Total - Net 50.078 52.839 3.619 2.836 0.26
Property/Plant/Equipment, Total - Gross 52.138 53.631 3.869 3.003 0.316
Accumulated Depreciation, Total -2.06 -0.792 -0.25 -0.167 -0.056
Goodwill, Net 3.736 3.736 3.736 3.736 3.736
Intangibles, Net 0 8.8 8.8 8.8
Other Long Term Assets, Total 12.35 9.667 4.296 3.218 1.525
Total Current Liabilities 56.647 43.944 28.601 14.897 6.208
Accounts Payable 11.247 11.59 8.661 4.289 3.431
Accrued Expenses 45.016 31.383 19.53 10.608 2.554
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.384 0.971 0.41 0 0.223
Total Liabilities 105.507 90.553 56.973 25.881 16.228
Total Long Term Debt 0 0 0 0 0
Deferred Income Tax 0.853 1.622 2.48 2.463 2.463
Minority Interest 0.221 0.528 24.795 6.821 7.536
Other Liabilities, Total 47.786 44.459 1.097 1.7 0.021
Total Equity 433.803 363.954 308.582 61.6 24.77
Redeemable Preferred Stock 0 0 0 141.706 59.83
Common Stock 0.059 0.045 0.041 2.887 2.27
Retained Earnings (Accumulated Deficit) -596.365 -359.559 -200.834 -82.993 -37.33
Total Liabilities & Shareholders’ Equity 539.31 454.507 365.555 87.481 40.998
Total Common Shares Outstanding 59.2803 45.4908 41.0403 34.5015 34.5015
Short Term Investments 394.302 280.173 283.554
Additional Paid-In Capital 1031.46 723.593 509.339
Unrealized Gain (Loss) -1.353 -0.125 0.036
Other Current Assets, Total 0.659 0.243
Long Term Investments 21.213 37.495
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 563.929 410.226 451.933 433.89
Cash and Short Term Investments 552.986 392.519 437.371 421.726
Cash & Equivalents 266.558 36.28 43.069 42.551
Short Term Investments 286.428 356.239 394.302 379.175
Total Receivables, Net 1.81 8.293
Accounts Receivable - Trade, Net
Prepaid Expenses 8.222 8.474 14.562 12.164
Total Assets 621.444 489.342 539.31 529.193
Property/Plant/Equipment, Total - Net 43.234 44.355 50.078 50.673
Property/Plant/Equipment, Total - Gross 45.998 47.448 52.138 52.374
Accumulated Depreciation, Total -2.764 -3.093 -2.06 -1.701
Goodwill, Net 3.736 3.736 3.736 3.736
Intangibles, Net
Other Long Term Assets, Total 10.545 12.122 12.35 12.859
Total Current Liabilities 51.759 56.358 56.647 54.061
Accounts Payable 12.305 12.818 11.247 9.82
Accrued Expenses 38.832 43.115 45.016 43.893
Notes Payable/Short Term Debt 0 0 0 0
Other Current Liabilities, Total 0.622 0.425 0.384 0.348
Total Liabilities 98.303 103.855 105.507 100.689
Total Long Term Debt 0 0 0 0
Deferred Income Tax 0 0.756 0.853 1.225
Minority Interest 0.141 0.178 0.221 0.234
Other Liabilities, Total 46.403 46.563 47.786 45.169
Total Equity 523.141 385.487 433.803 428.504
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.07 0.059 0.059 0.057
Additional Paid-In Capital 1295.52 1045.57 1031.46 972.111
Retained Earnings (Accumulated Deficit) -772.111 -659.584 -596.365 -541.394
Other Equity, Total -0.338
Total Liabilities & Shareholders’ Equity 621.444 489.342 539.31 529.193
Total Common Shares Outstanding 70.6037 59.4423 59.2803 57.0023
Other Current Assets, Total 0.911 0.94 0 0
Long Term Investments 0 18.903 21.213 28.035
Unrealized Gain (Loss) -0.556 -1.353 -2.27
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -237.113 -166.093 -118.548 -46.378 -23.432
Cash From Operating Activities -163.751 -154.093 -86.825 -39.143 -24.251
Cash From Operating Activities 1.426 0.544 0.16 0.111 0.051
Non-Cash Items 59.453 -5.101 23.702 0.617 0.308
Cash Taxes Paid 0.012 0.02 0.018 0.015 0.004
Changes in Working Capital 13.252 16.557 7.844 6.507 -1.178
Cash From Investing Activities -114.18 -18.115 -284.832 -0.352 -0.227
Capital Expenditures -2.548 -6.107 -0.758 -0.352 -0.227
Cash From Financing Activities 261.043 178.521 360.439 81.83 9.472
Financing Cash Flow Items 0 -1.146 18.424 -0.046 0
Issuance (Retirement) of Stock, Net 261.043 179.667 342.015 81.876 9.472
Net Change in Cash -16.888 6.313 -11.218 42.335 -15.006
Deferred Taxes -0.769 0 0.017
Other Investing Cash Flow Items, Total -111.632 -12.008 -284.074
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -63.262 -237.113 -182.129 -127.629 -59.237
Cash From Operating Activities -49.283 -163.751 -126.422 -93.223 -50.196
Cash From Operating Activities 0.36 1.426 1.067 0.692 0.344
Non-Cash Items 17.735 59.453 45.371 34.074 12.044
Changes in Working Capital -4.019 13.252 9.269 -0.36 -3.347
Cash From Investing Activities 42.121 -114.18 -102.286 -122.304 19.796
Capital Expenditures -2.548 -2.388 -0.728 -0.45
Other Investing Cash Flow Items, Total 42.121 -111.632 -99.898 -121.576 20.246
Cash From Financing Activities 0.373 261.043 211.302 210.713 1.258
Financing Cash Flow Items 0 0
Issuance (Retirement) of Stock, Net 0.373 261.043 211.302 210.713 1.258
Net Change in Cash -6.789 -16.888 -17.406 -4.814 -29.142
Deferred Taxes -0.097 -0.769
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Matrix Capital Management Company, LP Investment Advisor/Hedge Fund 19.7707 13959973 4760000 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 14.3315 10119378 1661800 2023-06-30 LOW
Eventide Asset Management, LLC Investment Advisor 11.0666 7814039 936236 2023-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.9685 4920437 688558 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.0323 3553312 495870 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.4653 3152914 320891 2023-06-30 LOW
Capital International Investors Investment Advisor 4.4297 3127758 0 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 3.7516 2648978 482312 2023-06-30 LOW
Avidity Partners Management LP Hedge Fund 3.3055 2334000 -595300 2023-06-30 HIGH
Citadel Advisors LLC Hedge Fund 3.0156 2129296 799303 2023-06-30 LOW
Decheng Capital Management III (Cayman) LLC Investment Advisor 2.9735 2099583 275000 2023-06-30 LOW
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 2.8583 2018234 531236 2023-06-30 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 2.8316 1999354 -11055 2023-06-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 2.7028 1908444 -1451885 2023-06-30 LOW
AllianceBernstein L.P. Investment Advisor/Hedge Fund 1.8715 1321435 31139 2023-06-30 LOW
PRIMECAP Management Company Investment Advisor 1.5737 1111150 -17770 2023-06-30
Cormorant Asset Management, LP Hedge Fund 1.5508 1095000 1095000 2023-06-30 LOW
Woodline Partners LP Hedge Fund 1.5507 1094974 -1070577 2023-06-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.512 1067601 171676 2023-06-30 LOW
Tybourne Capital Management (HK) Limited Hedge Fund 1.3617 961486 -670803 2023-06-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Zentalis Pharmaceuticals Company profile

About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Zentalis Pharmaceuticals Inc revenues was not reported. Net loss increased 35% to $158.7M. Higher net loss reflects Research & Development Expense - Balanci increase of 88% to $145.9M (expense), Stock-based Compensation in R&D increase from $7.3M to $20.9M (expense), Selling, General & Administrative Expens increase of 31% to $23.7M (expense).

Industry: Bio Therapeutic Drugs

1359 Broadway, Suite 801
NEW YORK
NEW YORK 10018
US

Income Statement

  • Annual
  • Quarterly

News

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

People also watch

Oil - Crude

82.20 Price
-0.080% 1D Chg, %
Long position overnight fee 0.0269%
Short position overnight fee -0.0488%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

17,981.30 Price
+0.000% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Gold

2,153.38 Price
-0.330% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.59 Price
-4.530% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading